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Abstract
Osteolineage cell-derived extracellular vesicles (EVs) play a regulatory role in he-
matopoiesis and have been shown to promote the ex vivo expansion of human he-
matopoietic stem and progenitor cells (HSPCs). Here, we demonstrate that EVs from 
different human osteolineage sources do not have the same HSPC expansion promot-
ing potential. Comparison of stimulatory and non-stimulatory osteolineage EVs by 
next-generation sequencing and mass spectrometry analyses revealed distinct mi-
croRNA and protein signatures identifying EV-derived candidate regulators of ex 
vivo HSPC expansion. Accordingly, the treatment of umbilical cord blood-derived 
CD34+ HSPCs with stimulatory EVs-altered HSPC transcriptome, including genes 
with known roles in cell proliferation. An integrative bioinformatics approach, which 
connects the HSPC gene expression data with the candidate cargo in stimulatory 
EVs, delineated the potentially targeted biological functions and pathways during 
hematopoietic cell expansion and development. In conclusion, our study gives novel 
insights into the complex biological role of EVs in osteolineage cell-HSPC crosstalk 
and promotes the utility of EVs and their cargo as therapeutic agents in regenerative 
medicine.
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1 |  INTRODUCTION
Hematopoietic stem cells (HSCs) are multipotent cells 
that have the capacity to self-renew and replenish the en-
tire blood system. Accordingly, HSCs are widely used in 
hematopoietic stem cell transplantations in patients with 
high-risk hematological malignancies.1 Umbilical cord 
(UC) blood is an alternative source of HSCs for both pedi-
atric and adult patients in need for a transplant and lacking 
an HLA-matched related or unrelated donor. Interestingly, 
UC-derived HSCs are characterized by its rapid availability 
and less stringent human leucocyte antigen match require-
ment. However, UC grafts contain a low number of HSCs, 
resulting in delayed hematopoietic recovery and increased 
patient morbidity and mortality, particularly in adult pa-
tients.2,3 Development of ex vivo culture systems that sup-
port UC-derived HSC expansion is a promising approach 
to improve engraftment and consequent post-transplanta-
tion recovery.4,5
Recent studies reported the success of improved ex 
vivo HSC expansion by mimicking the bone marrow niche, 
where HSC fate determination is tightly regulated.6,7 
Osteolineage cells, including primitive mesenchymal cells 
and bone-forming immature and mature osteoblasts, rep-
resent one of the critical niche components that support 
self-renewal and proliferation of HSCs, as well as hema-
topoietic stem and progenitor cells (HSPCs) in vivo.8-13 
Osteolineage cell-derived secreted factors and adhesion 
molecules yield robust in vitro proliferation of HSCs with 
long-term repopulation ability stressing the importance of 
discovering other osteolineage cell components that can 
support the growth factor-based expansion culture sys-
tems.12-17 Increasing number of studies report the role of 
extracellular vesicle (EV)-mediated intercellular communi-
cation within the hematopoietic system.18-22 EVs are small 
cellular compartments that regulate the function of their 
targets by transferring bioactive lipids, proteins, mRNAs, 
long non-coding RNAs and small non-coding RNAs, in-
cluding microRNAs (miRNAs), between cells.23,24 We 
previously demonstrated that human osteoblast-derived 
EVs retain HSPC-supporting capacity ex vivo, as revealed 
by long-term cultures and in vivo repopulation assays.25 
However, the molecular mechanisms, by which EVs reg-
ulate the communication between osteolineage cells and 
HSPCs, still remains to be elucidated.
In this study, we focused on understanding the key reg-
ulatory human osteolineage EV components that modulate 
the survival, proliferation, and differentiation of human 
CD34+ UC-HSPCs. In an effort to generate a candidate 
EV cargo list, we first investigated the UC-HSPC sup-
porting capacity of EVs secreted by different human os-
teolineage cells. Then, we compared the proteomics and 
miRNA profiles between stimulatory and non-stimulatory 
EVs by proteomics analyses and next-generation sequenc-
ing, respectively. Furthermore, we studied the effect of 
stimulatory EVs on the gene expression of UC-HSPCs by 
next-generation sequencing. Lastly, we employed compre-
hensive integrative bioinformatics analyses to define and 
propose biological pathways that are dynamically regulated 
by stimulatory EV cargo in UC-HSPC fate regulation.Taken 
together, our findings demonstrate that fetal calvaria osteo-
blast EVs prove to be powerful tools to expand UC-HSPCs 
ex vivo. This information will likely generate knowledge 
that is not only relevant for HSC expansion, but also holds 
the promise of modulating other types of stem cells for re-
generative medicine purposes in the future.
2 |  MATERIALS AND METHODS
2.1 | Cell culture
Simian virus 40-immortalized human osteoblast cells from 
fetal calvaria, SV-HFO cells,26 were seeded at a density of 
1 × 104 cells/cm2 and cultured in α-MEM (GIBCO, Paisley, 
UK) supplemented with 20 mM of HEPES, pH 7.5 (Sigma, 
St. Louis, MO, USA), streptomycin/penicillin, 1.8  mM 
CaCl2 (Sigma), 10 mM of β-glycerophosphate (Sigma) and 
2% of FCS (GIBCO) at 37°C in a humidified atmosphere 
of 5% of CO2 for 12-14 days. The culture medium was re-
placed every 2-3 days. Simian virus 40-immortalized human 
osteoblasts from fetal limb tissue (hFOB 1.19 cells, ATCC 
CRL11372) were seeded at a density of 1.5  ×  104 cells/
cm2 and cultured in DMEM/F12 (Thermo Fisher Scientific, 
Waltham, MA, USA), supplemented with 2.5 mM of l-glu-
tamine, 0.3  mg/mL of G418, streptomycin/ penicillin, and 
10% of FCS at 34°C in a humidified atmosphere of 5% of 
CO2 for 24 hours. hMSC-TERT cells27 were seeded at a den-
sity of 1.5 × 104 cells/cm2 and cultured in MEM (Thermo 
Fisher Scientific), supplemented with streptomycin/penicil-
lin and 10% of FCS at 37°C in a humidified atmosphere of 
5% of CO2 for 24 hours. All cell lines were washed with 1X 
PBS and refreshed with their respective serum-free culture 
medium 24 hours prior to EV isolation. All experiments with 
human UC were performed in accordance with the Dutch 
law on Medical Scientific Research with Humans and ap-
proved by the Medical Ethical Committee of the Erasmus 
University Medical Center (MEC-2009-410), Rotterdam, the 
Netherlands and written informed consent from the moth-
ers was obtained prior to UC donation. UC was collected 
in Erasmus University Medical Center using Stemcare/CB 
collection blood bag system (Fresenius Kabi Norge AS, 
Halden, Norway). Within 48 hours after collection, mononu-
clear cells were isolated using ficoll (Lymphoprep, Fresenius 
KabiNorge AS). CD34+ cells and viable DAPI-Lin-CD34+
CD38lowCD45RAlowCD90+ cells were isolated as described 
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previously.28 CD34+ cells and CD34+CD90+ cells were cul-
tured in either serum-free Cellgenix GMP SCGM (Cellgenix, 
Freiburg, Germany) or Glycostem Basic Growth Medium 
(Glycostem, Oss, the Netherlands) supplemented with SCF 
(50 ng/mL, Cellgenix) and Flt3L (50 ng/mL, Cellgenix), with 
or without EVs at 37°C in a humidified atmosphere of 5% of 
CO2. Cells were refreshed every 2-3 days.
2.2 | EV isolation and characterization
EVs were isolated from 20 mL conditioned medium by low 
speed centrifugation (1500 rpm, 5 minutes; 4500 rpm, 10 min-
utes) followed by ultracentrifugation (20 000 g, 30 minutes; 
100 000 g, 1 hour at 4°C) of the supernatant using the SW32Ti 
rotor (Beckman Coulter, Fullerton, CA, USA). Transmission 
electron microscopy (TEM) images were taken by negative 
staining of the purified EVs. Freshly carbon sputtered and 
formvar coated copper grids were incubated on EV prepara-
tions, washed rapidly in water and contrasted with (3.5%) ura-
nyl acetate. Grids were blotted and dried before the analysis 
using a Tecnai T12 G2 Biotwin at 120 kV. EV size distribu-
tion and concentration was measured with NanoSight LM10 
(Nanosight Ltd., Amesbury, UK) equipped with a 405  nm 
laser. Each sample was tracked for 60 seconds with five rep-
etitions. The data were processed by NTA 2.3 software.
2.3 | Immunoblot analysis
Protein samples were prepared by mixing the EVs (in PBS) 
with 6X reducing sample buffer immediately after isolation. 
EV proteins (1.8 µg of total protein/sample) were separated 
by SDS-PAGE at 200  V and transferred onto a nitrocellu-
lose membrane (Hybond-ECL, Amersham Biosciences, 
Buckinghamshire, UK). After blocking non-specific signal 
with 5% of BSA in TBS/ 0.1% of Tween-20, the membrane 
was incubated with primary antibodies against annexin A2 
(ANXA2; rabbit polyclonal. 1:500, Abcam, Cambridge, UK). 
Membranes were probed with secondary antibody conju-
gated with IRDye 800CW (1:5000, goat anti-rabbit, LI-COR, 
Lincoln, NE, USA) using Odyssey Infrared Imaging System 
according to the manufacturer's instructions (LI-COR).
2.4 | RNA isolation and quantitative real-
time PCR
Total EV-RNA was isolated using the TRIzol reagent 
(Thermo Fisher Scientific) according to the manufacturer's 
instructions. RNA concentration was determined using 
Nanodrop (Thermo Fisher Scientific) and size distribution 
was checked on an Agilent Bioanalyzer RNA 6000 Pico chip 
(Thermo Fisher Scientific). RNA from CD34+UC-HSPCs 
was isolated using NucleoSpin RNA XS kit (Macherey-
Nagel, Duren, Germany) according to the manufacturer's in-
structions. Quantitative real-time PCR was performed using 
the SYBR Green (Eurogentec, Seraing, Belgium) kit, accord-
ing to the manufacturer's instructions. The following primer 
sequences were used:
Gene 
symbol
Forward sequence 
(5' → 3')
Reverse sequence 
(5' → 3')
CYSLTR2 GCAGCTGAAAGA 
CAGAGACCT
CCATACCTTGCA 
TGGACCTTCT
EGR1 AGCCCTACGA 
GCACCTGAC
TGGGTTGGTCATG 
CTCACTA
GAPDH CCGCATCTTCT 
TTTGCGTCG
CCCAATACGACCA 
AATCCGTTG
ITGAX CCTACGGAACC 
ACCATCACC
ACATGTCAGGTGC 
AGGGAAC
MAOA ATGACACCAAG 
CCAGATGGG
AAGTCGATCAGCT 
TTCCGGG
NFIB GTCCAGCCACAT 
CATATCACAG
TTGGCAGGATCATT 
GTGGCTT
S100A9 GGAATTCAAAGA 
GCTGGTGCG
AGCTGCTTGTCTGC 
ATTTGTG
2.5 | Next-generation sequencing and 
bioinformatic analysis of miRNAs
Sequencing of miRNAs was performed by Illumina MiSeq 
with samples prepared with the NEBNext Small RNA library 
preparation kit (New England Biolabs) according to the manu-
facturer's instructions. Small RNA libraries were quantified on 
a Bioanalyzer High Sensitivity DNA chip (Agilent) and sub-
sequently normalized and pooled. Single end sequencing was 
performed on a Miseq (Illumina) single read 50 cycles with 6 
cycles for the index read (>1 M reads/sample). Subsequently 
demultiplexing was done using  cassava configure call to 
FASTQ. Quality metrics on the resulting FASTQ files were 
generated using fastqc in combination with multiqc. Very 
sensitive adapter aware alignment was done using novoalign. 
Alignment rates were measured using the samtools software. 
Abundance estimation for small RNAs as well as hsa-miRNA 
selection was performed using feature counts. Principle com-
ponent analysis plots were generated using the R software. The 
sequencing data are available in the Gene Expression Omnibus 
(GEO) database repository (https://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE143613. Comparative anal-
yses of the EV data were obtained by querying the Vesiclepedia 
plugin provided by FunRich functional enrichment analysis 
tool (V3.1.3, 2018). IPA (Ingenuity Systems, www.ingen uity.
com) was used to classify the miRNA categories and predict 
target pathways and genes.
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2.6 | Next-generation sequencing and 
bioinformatic analysis of HSPC transcriptome
RNA sequencing and bioinformatic analysis was performed 
as previously described.29 In brief, sequencing RNA librar-
ies were prepared with the TruSeq RNA Sample Prep Kit v2 
(Illumina, San Diego, CA, USA) according to the manufac-
turer's instructions. The concentration and size distribution of 
the libraries was determined on an Agilent Bioanalyzer DNA 
1000 chip (Thermo Fisher Scientific), and verified with Qubit 
fluorometry (Thermo Fisher Scientific). Libraries were loaded 
onto flow cells at concentrations of 8-10 PM to generate clus-
ter densities of 700 000/mm2 following the standard protocol 
for the Illumina cBot and cBot Paired-end cluster kit version 
3. Flow cells were sequenced as 51 × 2 paired end reads on an 
Illumina HiSeq 2000 using TruSeq SBS sequencing kit ver-
sion 3 and HCS v 2.0.12 data collection software. Base-calling 
was performed using Illumina's RTA version 1.17.21.3. The 
sequencing data were analyzed using CAP-miRSeq v1.1. 
Normalization (counts per million mapped reads, CPM; and 
reads per kilobase pair per million mapped reads, RPKM) 
analysis was performed using edgeR 2.6.2. The data from 
the replicates were combined as averages of the normalized 
read values, and only transcripts with CPM ≥ 1 for all repli-
cates were included in the analysis. The sequencing data are 
available in the Gene Expression Omnibus (GEO) database 
repository (https://www.ncbi.nlm.nih.gov/geo/) under acces-
sion number GSE145178. DAVID Bionformatics Resources 
v 6.7 was used to categorize the proteins into overrepresented 
GO annotations using the human expression dataset as a 
background.30,31 IPA was used to predict target pathways and 
analyze the interaction between EV cargo and CD34+ HSPC 
genes using the path explorer tool in My Pathway analysis.
2.7 | Mass spectrometry and bioinformatic 
analysis of proteins
Tryptic peptides were prepared according to the method de-
scribed by Kulak et al with some adjustments.32 Briefly, EVs 
were lysed in 2x concentrated (2%) SDC lysis buffer (Sigma 
Aldrich, Germany), 20  mM of TCEP (Thermo Scientific), 
80 mM of ChloroAcetamide (Sigma Aldrich), and 200 mM of 
TRIS-HCl pH 8.0 (Life Technologies, UK), boiled at 95° for 
5 minutes and sonicated for 10 cycles of 30  seconds on/off in 
a Bioruptor (Diagenode, Belgium). After an overnight diges-
tion with 100  ng of Trypsin-LysC (Promega, USA) at room 
temperature, sampleswereacidifiedwith 10% trifluoroaceticacid 
(Thermo Scientific) and loaded on in-house prepared SDB-RPS 
STAGEtips (Empore, USA). The tips werewashedwithethyl-
acetate (Sigma Aldrich) and 0.2% trifluoroaceticacid (Thermo 
Scientific), and then, the peptides were eluted in three fractions 
by increasing concentrations (100 and 150 mM) of ammonium 
formate (VWR Chemicals, Belgium) or 5% (v/v) of ammonium 
hydroxide (Merck Millipore, Germany) and acetonitrile (40%, 
60% and 80% v/v) (BioSolve, France). Sample volume was re-
duced by SpeedVac and supplemented with 2% of acetonitrile, 
0.1% of TFA to a final volume of 10 μL. About 3 μL of each 
sample was injected for MS analysis. Tryptic peptides were sepa-
rated by nanoscale C18 reverse phase chromatography coupled 
on line to an Orbitrap Fusion LumosTribrid mass spectrometer 
(Thermo Scientific) via a nanoelectrospray ion source (Nanospray 
Flex Ion Source, Thermo Scientific). All data were acquired with 
Xcalibur 4.1 software. The raw mass spectrometry files were 
processed with the MaxQuant computational platform, 1.5.3.30. 
Proteins and peptides were identified using the Andromeda 
search engine by querying the human Uniprot database (down-
loaded March 2017). Standard settings with the additional options 
match between runs, Label Free Quantification (LFQ), and only 
unique peptides for quantification were selected. The data were 
filtered for potential contaminants, reverse hits, and ‘only identi-
fied by site’ using Perseus 1.6.5.0.33 The proteins were filtered 
for three valid values in at least one of the experimental groups. 
Missing values were imputed by normal distribution (width = 0.3, 
shift = 1.8), assuming these proteins were close to the detection 
limit. The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the PRIDE34 part-
ner repository with the dataset identifier PXD017172. A volcano 
plot from a double-sided t test (FDR 0.05 and S0 of 2) was used to 
determine significant differences between the sEV and hEV sam-
ples. PANTHER 14.1 classification system and FunRich were 
used to categorize the proteins into overrepresented processes.
2.8 | Flow cytometry
Absolute numbers of viable human CD34+ cells were deter-
mined by a single platform flow cytometric assay using anti-
FITC-CD45, anti-CD34-PE, and Stem-Count Fluorospheres 
from the Stem-Kit Reagents kit (Beckman Coulter) and 
DAPI (Sigma). The frequencies of human phenotypic HSCs 
were determined using anti-Lin-FITC, anti-CD38-APC, 
anti-CD90-PE (Thermo Fisher Scientific), anti-CD34-PE-
Cy7, anti-CD45RA-APC-H7 (BD Biosciences), and DAPI. 
All samples were analyzed using BD FACSCanto II (BD 
Biosciences), and the data were analyzed using FlowJo soft-
ware (Tree Star, Inc, Ashland, OR, USA).
2.9 | Statistics
The results were described as mean  ±  SD based on at least 
two independent experiments performed with independent EV 
isolations and/or different UC donors. Significance was calcu-
lated using Student's t test, and P values < .05 were considered 
significant.
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3 |  RESULTS
3.1 | Characterization of EVs secreted by 
different osteolineage cells
To identify regulatory EV components that support human 
UC-HSPC expansion, we used two human fetal osteoblast 
cell lines of different origin, fetal calvaria-derived SV-HFO 
(sOB), and fetal limb tissue-derived hFOB 1.19 (hOB) cells, 
as well as human adult bone marrow-derived mesenchymal 
stem cell line (hMSC-TERT) as EV sources. Throughout this 
study, the three different EV populations secreted by sOBs, 
hOBs, and hMSC-TERTs are referred to as sEVs, hEVs, and 
mEVs, respectively. EVs were isolated from the conditioned 
serum-free cell culture medium by a series of centrifuga-
tion steps and verified by morphological and molecular 
characterization.
TEM analysis showed that all EV populations had spher-
ical vesicular structures in wide ranges of diameters with a 
surrounding lipid bilayer characteristic of EVs (Figure 1A-C). 
According to the nanoparticle tracking analyses (Figure 
1A-C) sEVs were more heterogenous in size with slightly 
larger mean size of 180 nm compared to the smaller hEVs 
of 155  nm and mEVs of 140  nm (Supporting Information 
Table 1). Interestingly, sOBs secreted more EVs than hOBs 
and hMSC-TERTs did in the given culture conditions, both 
in absolute terms as well as on a per cell basis. The major-
ity of the EVs were smaller than 200  nm for all the three 
EV populations, as expected from the centrifugation proto-
col. However, the percentage of larger EVs co-sedimenting 
at 100 000 g was higher in sEVs (26% compared to 14% in 
hEVs and 10% in mEVs), in accordance with TEM images 
(Figure 1D).Western blot analysis in Figure 1E further ver-
ified the presence of EVs by testing for the known vesicle 
marker ANXA2 in all three EV populations.35 Furthermore, 
representative Bioanalyzer electropherograms showed the 
typical RNA size distribution profiles for EVs, which were 
enriched with small RNAs (Figure 1F-H), and lacked the 
rRNA peaks characteristic of their parental cells (Figure 1I-
K). These results indicate that osteoblasts and MSCs release 
EVs matching the characteristics of EVs.
3.2 | EVs from different osteolineage 
sources do not have same HSPC 
expansion potential
Next, we investigated the potency of the different osteoline-
age EVs to promote ex vivo expansion of human UC-HSPCs. 
CD34+-selected UC-HSPCs were expanded in growth fac-
tor (SCF and Flt3L)-driven serum-free expansion cultures 
for 10  days with or without EVs. In the absence of EVs, 
growth factor-containing medium alone induced a 6.1-fold 
and 3.33-fold expansion of total number of viable nucle-
ated cells (TNCs) (Figure 2A) and CD34+ cells(Figure 2B), 
respectively. Fold change (FC) expansions of TNCs and 
CD34+ cells were not significantly altered by the addition 
of neither hEVs nor mEVs, at any given EV concentration. 
However, treatment of cells with the low concentration of 
sEV (0.2 × 107 EVs/μL) induced a small but significantly en-
hanced number of TNCs (P < .05). Moreover, a five-fold in-
creased sEV concentration resulted in 13.44-fold expansion 
of TNCs, and 7.77-fold expansion of CD34+ cells, leading to 
2.42-fold more CD34+ cells after 10 days of culture, as com-
pared to the control cultures(P < .005), showing a concentra-
tion dependent effect on cell expansion.We also counted the 
level of exhaustion of the most immature CD34+ cell subset 
after 10 days by multicolour flow cytometry using markers for 
primitive HSPCs (Lin- CD34+ CD38low CD45RAlow CD90+), 
referred to as phenotypic HSCs (Supporting Information 
Figure S1). Similar to TNCs and CD34+ cells, treatment with 
hEVs and mEVs did not alter the absolute numbers of phe-
notypic HSCs compared to the control cultures supplemented 
only with SCF and Flt3L. On the contrary, sEVs increased 
the number of phenotypic HSCs compared to the control on 
day 10. Together, these findings demonstrate the unique and 
strong potency of fetal calvaria osteoblast-derived sEVs to 
promote growth-factor-driven expansion of both CD34+ UC-
HSPCs and phenotypic HSCs, and show that EV-effect is pa-
rental cell type-specific.
3.3 | sEVs contain an overrepresented set of 
miRNAs compared to hEVs
MiRNAs are key players in maintaining the fine balance 
between the number of stem cells and their differenti-
ated progeny.36,37 To delineate the key EV components 
that support UC-HSPC expansion, we compared the 
miRNA profiles of stimulatory and non-stimulatory EVs 
using next-generation sequencing. In an effort to define 
a selective list of candidate sEV-miRNAs responsible for 
UC-HSPC support, we focused only on sEVs and hEVs, 
which derive from extensively characterized immortal-
ized osteoblasts. Interestingly, the majority of the cel-
lular miRNAs were shared between the two osteoblastic 
parental cells (88.4% of sOB- and 83.2% of hOB-derived 
miRNAs), and showed similarities in cellular abundance 
(Supporting Information Figure S2A).In total, we detected 
672 mature miRNAs in all replicates for at least one of 
the samples and 317 miRNAs are detected in all samples 
(Figure 3A). Smaller portions of cellular miRNAs were 
represented in their corresponding EVs: only 76.1% (427 
out of 561) of sOB-derived miRNAs and 57% (340 out of 
596) of hOB-derived miRNAs were represented in sEVs 
and hEVs, respectively. The expression level of vesicular 
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F I G U R E  1  Characterization of EVs secreted by diverse human osteolineage cells. A-C, Nanoparticle tracking analysis shows the size 
distribution and concentration of (A) sEVs, (B) hEVs and (C) and mEVs. (N = 3). Representative TEM images (magnification× 49 000) confirm 
the morphology of EVs. Scale bar: 500 nm. D, The percentage of small (<200 nm), medium (200-450 nm) and large (>450 nm) EVs varies 
between the three different EV populations. E) Western blot analysis of EV proteins (1.8 μg/lane) in sEVs, hEVs and mEVs using an antibody 
against ANXA2, a common EV marker. F-K, Representative Agilent Bioanalyzer electropherograms show the size distribution of total RNA 
extracted from (F) sEVs, (G) hEVs, (H) mEVs, (I) sOBs, (J) hOBs and (K) hMSC-TERTs, and FU, fluorescent units. (N = 3)
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miRNAs was a reflection of the cellular abundance for both 
EV populations (Supporting Information Figure S2B,C). 
Nevertheless, 45 miRNAs in sEVs and 43 miRNAs in hEVs 
(among which 22 are shared) were significantly (P < .05) 
more abundant (FC ≥ 2) in EVs compared to their parental 
cells (FC ≥ 2, P <  .05), suggesting selectivity of vesicu-
lar cargo packaging. Principal component analysis verified 
the high similarity of the two osteoblastic cell lines on a 
molecular level, while the clusters of miRNAs found in 
sEVs and hEVs separated from each other as well as from 
their parental cells (Figure 3B).These results indicate that 
molecularly very similar osteoblastic cell lines have differ-
ent EV miRNA loading mechanisms, which is independent 
of intracellular miRNA levels.
Next, we compared the miRNA content of sEVs and 
hEVs and followed a selection strategy to generate a list 
of candidate sEV-miRNAs, which may drive UC-HSPC 
expansion. Direct comparison of miRNA profiles of sEVs 
and hEVs revealed that 35 miRNAs are overrepresented 
in sEVs (FC  ≥  2, P  <  .05, Table 1), while 32 miRNAs 
were significantly depleted in sEVs (Figure 3C).We used 
Ingenuity Pathway Analysis (IPA) tool to determine the 
Mature miRNAs sEVs (Reads) hEVs (Reads) Log2 FC P value
miR-146a-5p 14 551.19 160.90 6.50 3.85E−06
miR-146b-5p 1063.74 21.49 5.63 1.62E−04
miR-32-5p 78.91 9.62 3.04 1.29E−02
miR-641 30.59 4.39 2.80 2.53E−02
let-7i-5p 27 918.11 5628.69 2.31 7.04E−04
miR-101-3p 1018.80 217.92 2.23 5.34E−03
miR-3615 40.43 9.82 2.04 3.45E−02
miR-29b-3p 176.45 43.11 2.03 3.00E−03
miR-30a-5p 5788.05 1518.24 1.93 3.13E−03
let-7b-5p 1759.00 513.11 1.78 5.18E−04
miR-31-5p 225.66 67.76 1.74 3.93E−04
miR-210 65.93 19.92 1.73 5.52E−03
miR-186-5p 365.18 119.47 1.61 1.02E−03
miR-331-3p 44.69 14.65 1.61 4.70E−03
miR-140-3p 1082.70 354.99 1.61 1.66E−03
miR-148a-3p 392.39 128.89 1.61 3.48E−02
miR-30e-5p 259.16 94.36 1.46 1.70E−02
miR-140-5p 177.31 65.37 1.44 5.93E−03
miR-378c 57.08 21.36 1.42 3.51E−02
miR-126-3p 234.67 88.43 1.41 7.23E−04
miR-19b-3p 117.37 46.36 1.34 1.30E−02
miR-3613-5p 41.63 16.57 1.33 2.97E−02
miR-598 19.70 8.18 1.27 4.44E−02
let-7b-3p 12.53 5.21 1.27 4.65E−02
let-7g-5p 7340.52 3236.38 1.18 2.36E−03
let-7f-5p 27 129.12 11 994.55 1.18 4.10E−03
miR-192-5p 229.02 103.88 1.14 2.11E−02
miR-28-5p 86.46 39.48 1.13 2.06E−04
miR-194-5p 51.00 23.67 1.11 4.85E−02
miR-143-3p 2697.25 1260.08 1.10 1.84E−02
miR-107 97.10 46.49 1.06 1.82E−02
miR-377-3p 10.34 5.02 1.04 3.93E−02
miR-502-3p 35.68 17.32 1.04 1.69E−02
miR-16-2-3p 150.76 73.31 1.04 2.76E−02
miR-29c-3p 13.52 6.69 1.01 3.75E−02
T A B L E  1  The list of sEV-miRNAs 
significantly (P < .05) enriched (FC ≥ 2) in 
sEVs compared to hEVs
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top diseases and biological functions associated with the 
enriched sEV-miRNAs. Target genes of the miRNAs en-
riched in sEVs were mostly annotated(P <  .05) to cancer 
and hematological disease, with most of the molecular 
and cellular functions annotated to cellular proliferation, 
including proliferation of lymphoma cells (miR-101-3p, 
miR-146a-5p, 19b-3p, 708-5p); cell death, including apop-
tosis of leukemic cells (miR-29b-3p);and cell cycle (let-
7a-5p, miR-92a-3p). It is important to note that 30 out of 
the35 overrepresented sEV-miRNAs contributed to less 
than 1% of the total reads, leading to questioning whether 
they are of biological significance. On the contrary, five 
overrepresented sEV-miRNAs, such as miR-146a-5p, miR-
30a-5p, let-7f-5p, let-7g-5p, and let-7i-5p, together made 
up 24.25% of the total reads (Figure 3D). Moreover, these 
five overrepresented sEV-miRNAs were also among the 
top 20 miRNAs in sEVs with the highest number of reads, 
making them highly interesting candidates for induction of 
UC-HSPC expansion (Figure 3E).
3.4 | sEVs and hEVs have distinct 
protein profiles
Next, we performed label-free mass spectrometry-based 
proteomics analysis to investigate the differential protein 
expression between stimulatory and non-stimulatory EVs. 
We identified a total of 3581 proteins in all replicates for at 
least one EV group after strict filtering; 2992 proteins were 
detected in sEVs and 3248 proteins in hEVs. The majority 
(2659) of the proteins was commonly found in both EVs 
and had similar abundances based on label-free quantifica-
tion (LFQ) values (Supporting Information Figure S3A).The 
majority (~93%) of the most commonly identified EV mark-
ers were detected at high level in both of EV groups.38 Top 
five most abundant proteins for both groups were the well-
defined EV markers: ANXA1, ANXA2, ANXA5, GAPDH, 
and HIST1H4A.
Volcano plot in Figure 4A shows the differentially ex-
pressed (FDR 0.05, S0 correction of 2—corrected for mul-
tiple testing) proteins between sEVs and hEVs. Among the 
420 differentially expressed proteins, 152 proteins were over-
represented in sEVs (Table 2), and 268 proteins in hEVs. 
To gain insights into the potential molecular functions of 
the overrepresented proteins in sEVs, we conducted several 
Gene Ontology (GO) enrichment analyses using different 
tools, such as PANTHER to define the general GO catego-
ries (Figure 4B) and FunRich to investigate the detailed func-
tional terms within a category (Figure 4C). The majority of 
the overrepresented sEV-proteins were annotated to binding 
(GO:0005488), including molecular functions such as DNA 
binding (HMGA1, HIST1H2BM, DDB2, MECP2) and cell 
adhesion (EPCAM, ICAM1, ITGA7); and structural molecule 
activity (GO:0005198), such as extracellular matrix struc-
tural constituent (LAMA1, THBS2, COL7A1, EMILIN1). 
The remaining enriched sEV-proteins were associated with 
transcription regulator activity (GO:0140110), such as DNA-
directed RNA polymerase activity (POLR3A, POLR1D); and 
molecular function regulator (GO:0098772), such as pepti-
dase activity (DPP4, PMPCA). On the contrary, hEVs were 
significantly enriched with proteins mainly involved in trans-
porter activity (GO:0005215), structural molecule activity 
(GO:0 005 198), and catalytic activity (GO:0003824) (Figure 
S3B). Figure 4D displays the sEV-proteins based on the top 
20 most abundant proteins among the 152 overrepresented 
proteins. Interestingly, LAMA1, ABI3BP, and HMGA1, 
which were the top five most enriched proteins, were also 
highly abundant, making them interesting candidates to 
study their significance for induction of cell expansion. Both 
miRNA and protein profiling analysespropose a list of highly 
abundant and overrepresented 5sEV-miRNAs and 3 sEV-pro-
teins that are associated with the role of fetal calvaria osteo-
blast-derived sEVs in supporting UC-HSPC proliferation.
F I G U R E  2  sEVs enhance ex vivo expansion of human 
CD34+UC-HSPCs. A and B, sEVs increase the ex vivo expansion of 
(A) total nucleated cells (TNCs) and (B) CD34+ cells after 10 days 
of incubation with SCF and Flt3L compared to cells cultured in the 
absence of EVs (control). hEVs and mEVs do not have a significant 
effect on expansion. Expansion is shown as fold change (FC) increase 
(mean ± SD) in total cell number compared to input on day 0. 
*P < .05, **P < .01, ***P < .005
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F I G U R E  3  Comparative next-generation sequencing miRNA profiling of stimulatory and non-stimulatory EVs. A, Venn diagram shows the 
number of miRNAs detected in parental cells and their corresponding EVs. Numbers in brackets show the total number of miRNAs detected in a 
given group. (N = 3). B, Principal component analysis confirms the similarities between the biological/technical replicates and shows the distinct 
variance between cellular and vesicular miRNA content. C, Volcano plot (significance vs. FC) shows the significantly (P < .05) enriched (FC ≥ 2) 
miRNAs in sEVs compared to non-stimulatory hEVs. D, MA plot (FC vs. mean expression) highlights the abundance of the selectively enriched 
sEV-miRNAs. The significantly overrepresented sEV-miRNAs, which are also among the top 20 most abundant sEV-miRNAs are shown in red. 
The rest of the significantly overrepresented sEV-miRNAs are shown in green. The rest of top 20 most abundant sEV-miRNAs are shown in blue. 
E, The 20 candidate sEV-miRNAs are displayed according to the normalized read count proportions (mean ± SD) of the top 20 most abundant 
sEV-miRNAs in connection to the color-coding of the MA plot
(A) (B)
(C)
(E)
(D)
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F I G U R E  4  Proteomic profiling of sEVs and hEVs. A, Volcano plot shows the significantly enriched (FDR 0.05, S0 correction of 2, corrected 
for multiple testing) proteins in sEVs compared to hEVs. Numbers in brackets denote the number of differentially expressed proteins. (N = 3). B, 
Heat map of significantly enriched sEV- and hEV-proteins categorized within with GO enrichment annotation based on molecular function. C, The 
percentages of proteins (enrichment factor) annotated to a subset of GO term for sEVs. D, The 20 candidate sEV-proteins are displayed according 
to the expression levels (mean ± SD) (red dots, right Y axis) of the top 20 most abundant sEV-proteins among the overrepresented 152 proteins  
as well as the enrichment levels (mean ± SD) (columns, left Y axis) of sEV-proteins compared to hEV-proteins
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3.5 | sEVs alter the gene expression of 
CD34+UC-HSPCs
Next, we investigated the alterations on the transcriptome 
profiling of CD34+UC-HSPCs after 24  hours treatment 
with sEVs. We identified 33 genes, of which 17 genes were 
upregulated and 16 genes were downregulated more than 
1.5-fold (P <  .05) inCD34+ cells by sEVs, as compared to 
the control treated cells (Figure 5A). We confirmed the dif-
ferential expression of selected genes by qPCR as shown in 
F I G U R E  5  Expression profiles of differentially expressed CD34+UC-HSPC genes upon sEV treatment. A, Volcano plot shows the 
CD34+UC-HSPC genes that are significantly (P < .05) regulated (FC ≥ 1.5) after 24 h of culture in the absence (control) and presence of sEVs 
(N = 2). Numbers in brackets denote the number of up-regulated (red, 17 genes) and down-regulated (green, 16 genes). B, Expression levels 
(mean ± SD) of selected CD34+UC-HSPC genes after 24 h of incubation in the presence of sEVs (N = 3). FC is determined compared to control 
and normalized to average GAPDH expression. The donors used for qPCR analysis are different than the ones used for mRNA sequencing. C-F, 
Expression profiles show the temporal pattern of gene expression as a response to sEV treatment defined by normalized read counts. sEVs enhance 
the (C) up-regulation and (E) down-regulation of CD34+UC-HSPC genes by control alone in 24 h. sEVs lower the control-induced (D) up-
regulation and (F) down-regulation of CD34+UC-HSPC genes by control alone in 24 h
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Figure 5B. Despite the donor-related variation, on average 
gene expression was in the same direction as determined by 
sequencing for all the tested genes. We then analyzed the pat-
terns of change in the expression levels of the 33 regulated 
genes between control and sEV-treated cells (t = 24 hours 
cell culture) compared to the expression levels at the start-
ing time-point (t = 0). We identified four different expres-
sion profiles: enhanced upregulation (Figure 5C), lowered 
upregulation (Figure 5D), enhanced downregulation (Figure 
5E), and lowered downregulation (Figure 5F) of endogenous 
(control) gene expression as a response to sEV-treatment 
in 24  hours. For the majority of the genes, sEV-treatment 
enhanced the endogenous upregulation or downregulation 
induced by culture conditions (Figure 5C,E). For a small 
number of genes, however, sEVs altered gene expression by 
lowering the extent of endogenous upregulation of MAOA 
and NFIB and TGFB1I1 (Figure 5D), and downregulation of 
BCL3, DUSP3, PHLDB2, PIM1, and S100A9 (Figure 5F).
According to GO analysis, the 33 regulated genes were 
mostly (P  <  .05) annotated to MAPK signalling pathway 
(CACNA1H, DUSP3, DUSP8, MAP3K6). Further investiga-
tion using IPA indicated that sEVs modulate the expression 
of CD34+ UC-HSPC genes mostly annotated (P  <  .05) to 
cellular development, cellular growth and proliferation, cell-
to-cell signaling and interaction, small molecule biochemis-
try, and cell cycle. A set of genes, including BCL3, EGR1, 
ITGAX, CYSLTR2, PIM1, and S100A9, were of particular 
interest as they are mainly related to the expansion of blood 
cells. These findings show that fetal calvaria osteoblast-de-
rived sEVs are capable of altering the expression pattern of 
cellular growth-related CD34+ UC-HSPC genes, supporting 
our previous studies reporting the proliferative effect of sEV 
cargo.25
3.6 | Candidate key molecular players of 
sEV function
To investigate the molecular basis of sEV-mediated gene 
regulation in UC-HSPCs, we correlated the sEV content 
to the regulated genes in UC-HSPCs using an integrative 
bioinformatics approach. We used IPA to build a network 
map showing the tentative molecular relationships between 
the sEV cargo, such as proteins and miRNAs, and the sEV-
regulated CD34+UC-HSPC genes (Figure 6).Notably, here, 
we only analyzed the highly abundant miRNAs found in 
sEVs with normalized read counts above 100, and correlated 
these miRNAs only to the downregulated genes in treated 
CD34+UC-HSPCs. Among the regulated genes, the high-
est number of EV cargo, including both miRNAs and pro-
teins, targeted EGR1. Furthermore, PHLDB2 and S100A9 
were the most common putative targets of the proteins alone. 
On the contrary, ZNF286B and NFIB were targeted by the 
highest number of miRNAs, with the former being targeted 
by miRNAs only. The majority of the mapped proteins were 
annotated to biological processes, such as cell communica-
tion (EPCAM, ICAM1), regulation of nucleic acid metabo-
lism (HMGA1, MECP2, ZNF22), and cell growth and/or 
maintenance (LAMA1, SPTAN1). Combined analysis of 
the mapped sEV-derived protein and miRNAcargo indicated 
that PI3K/AKT and PTEN signalling were among the top 
overrepresented canonical pathways that may be targeted 
in UC-HSPCs.Remarkably, all three of the candidate sEV-
proteins, speculated to contribute to the sEV-mediated UC-
HSPC support, were among the mapped proteins. Among 
these, LAMA1 was mapped to DUSP8, HMGA1 to EGR1, 
and ABI3BP to ABI3. On the contrary, among the candidate 
sEV-miRNAs only miRNAs of the let-7 family were mapped 
to an UC-HSPC gene:ZNF286. Together, these analyses link 
the fetal calvaria osteoblast-derived sEV cargo to the regula-
tion of CD34+ UC-HSPC gene expression, enabling valuable 
new insights into the molecular complexity of EV-mediated 
osteolineage-cell-HSPC crosstalk.
4 |  DISCUSSION
The discovery of specialized EVs delivering regulatory mol-
ecules to target cells has been the hallmark of a recently dis-
covered novel form of intercellular communication. Using 
comparative proteomics, miRNA sequencing, and bioinfor-
matics analyses, we showed that human fetal calvaria oste-
oblast-derived sEVs support human UC-HSPC expansion 
and are selectively enriched with a unique set of protein and 
miRNA cargo. Through an integrative bioinformatics ap-
proach, we unified the sEV cargo repositories with the sEV-
regulated CD34+UC-HSPC transcriptome and identified 
novel players and molecular mechanisms of EV-mediated 
osteolineage cell-HSPC crosstalk.
Increasing knowledge on key players of the bone marrow 
niche, where HSC self-renewal is supported, greatly contrib-
uted to the establishment of optimized expansion conditions 
that support expansion of HSPCs in culture.39-42 We previ-
ously demonstrated that osteoblast-derived EVs cooperate 
with hematopoietic growth factors not only to promote ex 
vivo proliferation, but also to preserve the repopulating ac-
tivity of CD34+HSPCs.25 However, not all niche cells secrete 
EVs with the same HSPC supporting potential. In an attempt 
to avoid interpretation of our results due to the possibility of 
isolated incidents of the selected cell line, we conducted our 
experiments using osteolineage cells of different origins. The 
addition of sEVs deriving from the fetal calvarias OBs sig-
nificantly increases the number of CD34+UC-HSPCs in ex-
pansion cultures by at least twofold. However, treatments with 
hEVs deriving from the limb tissue hOBs and immortalized 
MSC-derived mEVs do not improve growth factor-induced 
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UC-HSPC expansion. It is important to bear in mind that the 
effect of hEVs and mEVs may be masked by the intrinsic 
growth rate of the control alone. Moreover, contribution of 
internalized EVs to CD34 expression levels, as well as the 
effect of cellular processes, such as circadian rhythm and 
asymmetric cell division, on CD34 surface marker expres-
sion pattern should be further investigated to understand the 
differences between the EVs. The differential UC-HSPC 
growth promoting effects of sEVs, hEVs and mEVs is most 
likely attributed to the content differences between the EVs.
EV secretion is an evolutionarily conserved form of 
communication among cells, and therefore, most EVs 
share biologically relevant EV cargo regardless of the 
type of parental cells.43,44 Advancement of systematic and 
comprehensive studies has helped us identify the biologi-
cally active EV components and study their physiological 
F I G U R E  6  IPA network showing the direct relationship maps between the sEV cargo and sEV-regulated CD34+UC-HSPC genes. Green, 
down-regulated CD34+UC-HSPC genes; red, up-regulated CD34+UC-HSPC genes; black ovals, sEV-proteins; grey diamonds, sEV-miRNAs. The 
names of the candidate sEV-proteins and -miRNAs, which mapped to the regulated UC-HSPC genes are displayed on the map 
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relevance. Proteomic and sequencing analyses demonstrate 
selective incorporation of a different set of functional 
proteins and miRNAs inside sEVs and hEVs. Striking 
examples of candidate cargo include the highly abundant 
sEV-miRNAs, such as let-7i-5p, let-7f-5p, miR-146a-5p, 
let-7g-5p, and miR-30a-5p, as well as sEV-proteins, such 
as LAMA1, ABI3BP, and HMGA1. MiR-146a, the most 
overrepresented miRNA in sEVs, plays an important role in 
hematopoietic stem cell differentiation.45,46 Starczynowski 
et al showed that miR-146a expression is much higher in 
CD34+ cells compared to the CD34- precursor cells, lead-
ing to the inhibition of hematopoietic differentiation.47 
Interestingly, let-7 family members are known to be tightly 
cooperating with miR-99a/100 and miR-125b-1/2, which 
are also highly abundant in sEVs, to control hematopoietic 
growth.48 Remarkably, HMGA1 along with HMGA2 is a 
part of the Lin28-let7 pathway, which regulates fetal cell-
like stem cell maintenance in adult HSCs.49-51 The co-ex-
istence of let-7 and HMGA1 within EVs suggests that the 
EV cargo consists of a combination of functionally diverse 
structural and regulatory biomolecules that must work in 
concert to convey the final message.
The remarkable power of active sorting mechanism ren-
ders EVs with unique combinations of EV cargo that may 
act in concert to modulate the expression levels of their tar-
get genes. Understanding the role of EVs in hematopoiesis, 
therefore, requires unraveling the way EV regulators inter-
act with each other to regulate transcriptional networks. In 
accordance with HSPC support studies, sEV-regulated UC-
HSPC genes are mostly annotated to cell growth related pro-
cesses. Particularly, sEVs alter the expression patterns of key 
players of HSPC self-renewal, such as BCL3, EGR1, ITGAX, 
CYSLTR2, PIM1, and S100A9.17,52,53 Interestingly, some of 
these genes are among the tentative targets of the sEV cargo. 
The highest number of sEV cargo, including the candidate 
EV-protein and -miRNAs, targets EGR1, which encodes for 
a transcription factor that plays a key role in the regulation 
of hematopoietic homeostasis. Previous studies showed that 
EGR1 levels are high in quiescent cells and they are dra-
matically downregulated upon cell division.54 Accordingly, 
we demonstrate that EGR1 levels drop after 24 hours as the 
UC-HSPCs progress into cell cycle. Interestingly, the down-
regulation is further enhanced in the presence of sEVs most 
likely due to the ability of EVs to drive the cell division 
kinetics of HSPCs.25 S100A9 is another predominantly tar-
geted UC-HSPC gene. Previous reports showed that S100A9 
expression is upregulated during HSC maturation.55 Here, 
S100A9 levels are downregulated by sEVs, suggestive of 
an effort for EVs to maintain the cells in a more immature 
state. Moreover, NFIB is one the targets of the majority of 
sEV-miRNAs. The downregulation of NFIB has been shown 
to be critical during the transition of the immature HSCs to 
the multipotent progenitors.56 Previously, we demonstrated 
that osteoblast-EVs stimulate the expansion of the progen-
itor cells while maintaining the immature stem cell pool.25 
Although it is tempting to speculate a role for NFIB target-
ing in the expansion of the progenitors, further functional 
studies are needed to investigate the detailed molecular 
mechanisms.
In conclusion, the findings described in this study pro-
vide a comprehensive human fetal osteoblast-derived EV 
cargo repository useful for the functional exploration of 
EV-mediated regulation of osteolineage cell-HSPC cross-
talk.UC-HSPC expansion analyses combined with com-
parative omics studies identified candidate fetal calvaria 
osteoblast-derived sEV cargo, which provided novel in-
sights into the EV-driven molecular mechanisms that trig-
ger UC-HSPC expansion. However, it is still challenging 
to assess the extent to which individual or combinations 
of cargo contribute to these effects. Further investigation 
focusing on the generation of modified EVs devoid of par-
ticular candidates or engineered EVs loaded with selective 
cargo is promising to elucidate the biological roles of the 
EV cargo.
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